RxDoctor Payments Data

Eva Giro, MD

Internal Medicine · Marietta, OHNPI 1104821420

Payments from drug & device makers

$9,733in general payments, 2019–2025

Across 580 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • AbbVie$778
  • Amarin Pharma, Inc.$749
  • Boehringer Ingelheim$647
  • Lilly USA, LLC$536
  • plus $4K from 38 others

What the payments were for

  • Speaking & faculty fees$200%
  • Food & beverage$9,696100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,733 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$155,374
Medicare patients
429
Services billed
1,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$153,995
OzempicSemaglutide107$138,221
JardianceEmpagliflozin77$85,383
MounjaroTirzepatide44$58,459
XareltoRivaroxaban47$50,425
FarxigaDapagliflozin Propanediol53$48,313
TrulicityDulaglutide27$44,807
JanuviaSitagliptin Phosphate36$35,714
Repatha SureclickEvolocumab41$26,343
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$20,440
MyrbetriqMirabegron44$20,375
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$18,677
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$11,623
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$9,060
SynthroidLevothyroxine Sodium120$7,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$484$153,995148 claims
Novo NordiskOzempic$498$138,221107 claims
Lilly USA, LLCMounjaro, Trulicity$536$103,26571 claims
Boehringer IngelheimJardiance$647$85,38377 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,691$68,75485 claims
Johnson & JohnsonXarelto$292$50,42547 claims
MerckJanuvia, Dulera$177$39,85348 claims
Astellas Pharma US IncMyrbetriq$171$20,37544 claims
GSKAnoro Ellipta$96$18,67729 claims
AbbVieSynthroid, Linzess$778$13,515132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Marietta

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →